Review
Copyright ©The Author(s) 2017.
World J Hepatol. Feb 18, 2017; 9(5): 242-251
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.242
Table 6 Summary of studies with ≥ 40 patients who underwent hepatectomy for liver metastasis from breast cancer
Ref.YearPeriodNo. of patientsMST (mo)3-ysr (%)5-ysr (%)MDFS (mo)Factors associated with worse overall survival
Pocard et al[36]20001988-1997524249NRNRDisesase free interval ≤ 48 mo (univariate)
Elias et al[37]20031986-200054345034NRHormone receptor-negative
Adam et al[38]20061984-20048532NR3720Poor response to preoperative chemotherapy, R2, no repeat hepatectomy
Adam et al[10]120061983-200445445NR41NRNR
Hoffman et al[39]20101999-20084158684834Positive resection margin, disease-free interval < 24 mo
Abbott et al[40]20121997-20108657NR4414ER-negative, disease progression before hepatectomy
Groeschl et al[13]120121990-200911552522722NR
Mariani et al[41]20131988-20075191NRNRNRNon-hepatectomy3, bone metastasis4
Hoffmann et al[15]120152001-20124263NR53NRNR
Sadot et al[42]20161991-2014692502NR38229Lymph node metastasis in the primary tumor, absence of trastuzumab therapy, multiple liver metastases